BusinessClearside Biomedical, Inc. Announces Pricing of Public Offering of Common StockBy Nasdaq OMXDec 9, 2016, 2:20 PM UTC
BusinessClearside Biomedical, Inc. Announces Proposed Offering of Common StockBy Nasdaq OMXDec 7, 2016, 9:02 PM UTC
BusinessClearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular EdemaBy Nasdaq OMXNov 15, 2016, 1:24 PM UTC
BusinessClearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXNov 9, 2016, 12:00 PM UTC
BusinessClearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016By Nasdaq OMXNov 8, 2016, 9:30 PM UTC
BusinessClearside Biomedical, Inc. Names Rick McElheny as Vice President, Business DevelopmentBy Nasdaq OMXNov 8, 2016, 12:00 PM UTC
BusinessClearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) MeetingBy Nasdaq OMXOct 10, 2016, 11:00 AM UTC
BusinessClearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare ConferenceBy Nasdaq OMXSep 20, 2016, 8:30 PM UTC
